Search
26/08/2022
Usefulness of endonasal flaps and grafts in skull base surgery. Consensus document.
Moreno-Luna R, Mariño Sánchez F, Kaen A, Gras Cabrerizo JR, Mata Castro N, González García J, Villacampa Aubá JM, Cárdenas Ruiz-Valdepeñas E, Monjas Cánovas I, Del Cuvillo Bernal A, García Piñero A, Maza Solano JM, Fernández de Liesa R, Sánchez-Gómez S, Alobid I. Usefulness of endonasal flaps and grafts in skull base surgery. Consensus document.. Acta Otorrinolaringologica Espanola. 2022; 73(5)DOI:10.1016/j.otoeng.2021.02.004. PMID:36031110. IF:(Q/D).
01/06/2022
A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper
Zozaya, N, Villaseca, J, Abdalla, F, Calleja, MA, Diez-Martin, JL, Estevez, J, Garcia-Sanz, R, Martinez-Lopez, J, Sierra, J, Vera, R, Hidalgo-Vega, A. A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper. Clinical & Translational Oncology. 2022; 24(6)DOI:10.1007/s12094-021-02757-9. PMID:34997475. IF:3.400(Q3/6D).
12/05/2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
Burger, JA, Robak, T, Demirkan, F, Bairey, O, Moreno, C, Simpson, D, Munir, T, Stevens, DA, Dai, S, Cheung, LWK, Kwei, K, Lal, I, Hsu, EM, Kipps, TJ, Tedeschi, A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. LEUKEMIA & LYMPHOMA. 2022; 63(6)DOI:10.1080/10428194.2021.2020779. PMID:35014928. IF:2.600(Q3/7D).
21/03/2022
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma
Halwani, AS, Panizo, C, Isufi, I, Herrera, AF, Okada, CY, Cull, EH, Kis, B, Chaves, JM, Bartlett, NL, Ai, WY, De La Cruz-Merino, L, Bryan, LJ, Houot, R, Linton, K, Briones, J, Chau, I, von Keudell, GR, Lu, HL, Yakovich, A, Chen, M, Ter Meulen, JH, Yurasov, S, Hsu, FJ, Flowers, CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. LEUKEMIA & LYMPHOMA. 2022; 63(4)DOI:10.1080/10428194.2021.2010057. PMID:34865586. IF:2.600(Q3/7D).
01/03/2022
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
Hernandez-Boluda, JC, Pereira, A, Zinger, N, Gras, L, Martino, R, Paneesha, S, Finke, J, Chinea, A, Rambaldi, A, Robin, M, Saccardi, R, Natale, A, Snowden, JA, Tsirigotis, P, Vallejo, C, Wulf, G, Xicoy, B, Russo, D, Maertens, J, Daguindau, E, Lenhoff, S, Hayden, P, Czerw, T, McLornan, DP, Yakoub-Agha, I. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. BONE MARROW TRANSPLANTATION. 2022; 57(3)DOI:10.1038/s41409-021-01553-x. PMID:35066569. IF:4.800(Q1/2D).
23/02/2022
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Pinana, JL, Vazquez, L, Martino, R, de la Camara, R, Sureda, A, Rodriguez-Veiga, R, Garrido, A, Sierra, J, Ribera, JM, Torrent, A, Mateos, MV, de la Rubia, J, Tormo, M, Diez-Campelo, M, Garcia-Gutierrez, V, Alvarez-Larran, A, Sancho, JM, MartinGarcia-Sancho, A, Yanez, L, Simon, JAP, Barba, P, Abrisqueta, P, Alvarez-Twose, I, Bonanad, S, Lecumberri, R, Ruiz-Camps, I, Navarro, D, Hernandez-Rivas, JA, Cedillo, A, Garcia-Sanz, R, Bosch, F. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. LEUKEMIA & LYMPHOMA. 2022; 63(3)DOI:10.1080/10428194.2021.1992619. PMID:34668835. IF:2.600(Q3/7D).